文献速递主动脉疾病

Treovance覆膜支架用于血管腔内动脉瘤修复的全球上市后临床随访:RATIONALE注册研究一年结果

Global Post-Market Clinical Follow-up of the Treovance Stent-Graft for Endovascular Aneurysm Repair: One-Year Results From the RATIONALE Registry.
PubMed 文献 · J Endovasc Ther · 2018-10-03

全球多中心前瞻性RATIONALE注册研究纳入202例适合使用Treovance行血管腔内动脉瘤修复的腹主动脉瘤患者,评估其安全性和性能。技术成功率为96%(194/202),1年临床成功确认于194例(96%)患者,无动脉瘤相关死亡,30天无死亡,主要并发症发生率为1%,1年免于再干预的Kaplan-Meier估计值为95.6%(95% CI 91.4%至97.8%)。结论认为Treovance覆膜支架在真实世界环境中治疗肾下型腹主动脉瘤具有良好安全性和临床性能。

要点

  • 技术成功率为96%(194/202),8例患者术中存在未解决的I型内漏。
  • 1年临床成功确认于194例(96%)患者;6例有 new/persistent 内漏,2例无明确内漏的动脉瘤扩张。
  • 平均随访13.7±3.1个月(中位12.8),8例(4%)需再干预;13例(6.4%)死亡,无动脉瘤相关死亡。

核心结论

  • RATIONALE注册研究显示Treovance覆膜支架在真实世界环境中治疗肾下型腹主动脉瘤具有良好的安全性和临床性能。

研究设计与样本

  • 全球、多中心、前瞻性RATIONALE注册研究(ClinicalTrials.gov标识NCT03449875)纳入202例适合使用Treovance行血管腔内动脉瘤修复的腹主动脉瘤患者(平均年龄73.0±7.8岁;187例男性)。

主要发现

  • 技术成功率为96%(194/202);8例患者术中存在未解决的I型内漏。
  • 30天无死亡,主要并发症发生率为1%(1例心肌梗死和1例肠缺血)。
  • 1年临床成功确认于194例(96%)患者;8例中6例有new/persistent内漏,2例无明确内漏的动脉瘤扩张。
  • 平均随访13.7±3.1个月(中位12.8)期间,8例(4%)需再干预。
  • 1年时,免于再干预的Kaplan-Meier估计值为95.6%(95% CI 91.4%至97.8%);免于I/III型内漏为95.5%(95% CI 91.7%至97.6%);免于动脉瘤扩张为97.4%(95% CI 94.2%至98.9%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE:: To evaluate the safety and performance of the Treovance stent-graft. METHODS:: The global, multicenter RATIONALE registry ( ClinicalTrials.gov; identifier NCT03449875) prospectively enrolled 202 patients (mean age 73.0±7.8 years; 187 men) with abdominal aortic aneurysms (AAA) suitable for endovascular aneurysm repair (EVAR) using the Treovance. The composite primary safety endpoint was site-reported all-cause mortality and major morbidity. The primary efficacy outcome was clinical success. Further outcomes evaluated included technical success; stent-graft migration, patency, and integrity; endoleak; and aneurysm size changes. RESULTS:: Technical success was 96% (194/202); 8 patients had unresolved type I endoleaks at the end of the procedure. There was no 30-day mortality and 1% major morbidity (1 myocardial infarction and 1 bowel ischemia). Clinical success at 1 year was confirmed in 194 (96%) patients; 6 of 8 patients had new/persistent endoleaks and 2 had aneurysm expansion without identified endoleak. A total of 8 (4%) reinterventions were required during the mean 13.7±3.1 months of follow-up (median 12.8). At 1 year, the Kaplan-Meier estimate for freedom from reintervention was 95.6% (95% CI 91.4% to 97.8%). Other estimates were 95.5% (95% CI 91.7% to 97.6%) for freedom from endoleak type I/III and 97.4% (95% CI 94.2% to 98.9%) for freedom from aneurysm expansion. Thirteen (6.4%) patients died; no death was aneurysm related. CONCLUSION:: The RATIONALE registry showed favorable safety and clinical performance of the Treovance stent-graft for the treatment of infrarenal AAAs in a real-world setting.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Uberoi R, Setacci C, Lescan M, et al. Global Post-Market Clinical Follow-up of the Treovance Stent-Graft for Endovascular Aneurysm Repair: One-Year Results From the RATIONALE Registry. J Endovasc Ther. 2018. PMID: 30280649. doi:10.1177/1526602818803939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。